Drugs /

cd19car-cd28-cd3zeta-egfrt-expressing tn/mem-enriched t-lymphocytes

Back to Drugs List

Overview

NCI Definition [1]:
A preparation of genetically modified autologous lymphocytes comprised of CD62L-positive naïve and memory T-cells (Tn/mem), that are transduced ex vivo with a self-inactivating (SIN) lentiviral vector expressing a hinge-optimized chimeric antigen receptor (CAR) specific for the CD19 antigen and containing CD28 and CD3 zeta signaling domains, and a truncated form of the human epidermal growth factor receptor (EGFRt), with potential immunostimulating and antineoplastic activities. Upon isolation of peripheral blood lymphocytes (PBLs), transduction of the CD62L-positive T-lymphocytes, expansion ex vivo and reintroduction of the cells into the patient, the autologous CD19R(EQ)-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-cells target CD19-expressing tumor cells, thereby inducing selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies. Devoid of both ligand binding domains and tyrosine kinase activity, EGFRt both facilitates in vivo detection of the administered T-cells and can promote elimination of those cells upon a cetuximab-induced antibody dependent cellular cytotoxicity response. Tn/mem T-cells include naïve T-cells, central memory T-cells (Tcm) and stem cell memory T-cells (Tscm). CD19R(EQ) contains two point mutations in the immunoglobulin (Ig) G4 spacer region, thereby preventing recognition of the CAR by Fc receptors (FcRs).

Clinical Trials

View Clinical Trials for cd19car-cd28-cd3zeta-egfrt-expressing tn/mem-enriched t-lymphocytes

Cd19car-cd28-cd3zeta-egfrt-expressing tn/mem-enriched t-lymphocytes has been investigated in 4 clinical trials, of which 4 are open and 0 are closed. Of the trials investigating cd19car-cd28-cd3zeta-egfrt-expressing tn/mem-enriched t-lymphocytes, 3 are phase 1 (3 open) and 1 is phase 2 (1 open).

CD19 Expression, ERBB2 Amplification, and HER2 Overexpression are the most frequent biomarker inclusion criteria for cd19car-cd28-cd3zeta-egfrt-expressing tn/mem-enriched t-lymphocytes clinical trials.

Mantle cell lymphoma, acute lymphoblastic leukemia, and B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical hodgkin lymphoma are the most common diseases being investigated in cd19car-cd28-cd3zeta-egfrt-expressing tn/mem-enriched t-lymphocytes clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Cd19car-Cd28-Cd3zeta-Egfrt-Expressing Tn/mem-Enriched T-Lymphocytes
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating cd19car-cd28-cd3zeta-egfrt-expressing tn/mem-enriched t-lymphocytes and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
cd19r(eq)28zetaegfrt+ tn/tmem, cd19r(eq)28zetaegfrt+ tn/mem cells, cd19r(eq)28zetaegfrt+ tn/mem cells, autologous cd19car-cd28-cd3zeta-egfrt-expressing tn/mem-enriched t-lymphocytes, d19car-cd28-cd3zeta-egfrt-expressing tn/mem-enriched t-lymphocytes, cd19r(eq)28zeta/egfrt+ naive and memory t cells, cd19car-cd28-cd3zeta-egfrt-expressing tn/mem-enriched t cells
Drug Target(s) [2]:
CD19
NCIT ID [1]:
C133073

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.